Brasilia, Brazil, 26 December 2023 —MicroPort® NeuroTech™ has recently received approval for its Tubridge® Vascular Reconstruction Device (Tubridge®) from the Brazilian National Health Surveillance Agency (ANVISA).
Tubridge® is a dense-mesh stent applying the concept of flow diversion therapy, specifically designed for treating large or giant wide-necked complex intracranial aneurysms. Its unique structure, braided with 48/64 wires of nitinol alloy, ensures conformability and radiopacity of the product, while providing excellent wall-apposition and flexibility in pore deformation. Utilizing the principles of hemodynamics, Tubridge® diverts the blood flow in the aneurysm reducing impact on the aneurysm wall. This promotes endothelial cell growth along the stent's scaffold, gradually repairing the aneurysm neck and treating the aneurysm, thereby eliminating the risk of aneurysm rupture.
Tubridge® previously obtained approval in China in March 2018 and in Argentina in August 2023. In the future, MicroPort® NeuroTech™ will continue to invest in product innovation and technological research and development, aiming to provide a comprehensive solution for patients with cerebrovascular diseases across the globe.
About MicroPort® NeuroTech™
MicroPort® NeuroTech™ (MicroPort NeuroTech Limited; HKEX: 2172), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is committed to the research and development of high-end medical devices in the field of neurological interventional treatment with solutions that currently support over 100 cerebrovascular stenting procedures every day. In the future, MicroPort® NeuroTech™ will continue investing more resources in innovation and development to provide more high-quality and innovative cerebrovascular and neuro intervention solutions for doctors and patients.
More information is available at www.medneurotech.com.